85-year-old patient who maintained daily use of 81 mg of aspirin at time of stereotactic-guided core-needle biopsy of group of breast calcifications; pathologic assessment yielded atypical ductal hyperplasia.

 

85-year-old patient who maintained daily use of 81 mg of aspirin at time of stereotactic-guided core-needle biopsy of group of breast calcifications; pathologic assessment yielded atypical ductal hyperplasia. Left craniocaudal (CC) mammographic view obtained before (A) and after (B) biopsy show hematoma on postbiopsy image (arrow), measuring 1.2 cm.


May 11, 2023 — According to an accepted manuscript published in ARRS’ own American Journal of Roentgenology (AJR), frequencies of imaging-apparent and palpable hematoma were not significantly different between patients temporarily discontinuing versus maintaining antithrombotic therapy (AT).

“The findings support safety of continuing AT during breast core-needle biopsy (CNB),” wrote lead researcher Melissa Reichman, MD, of Weill Cornell Medicine at New York-Presbyterian Hospital, adding that patients who maintain AT should be counseled regarding risk of bruise.

This AJR accepted manuscript included 5302 patients (median age, 52 years) who underwent image-guided breast or axillary CNB between January 1, 2014 and December 31, 2019. From January 1, 2014 to December 31, 2016, patients temporarily discontinued all AT for 5 days before CNB; from January 1, 2017 to December 31, 2019, the cohort maintained AT during CNB. After reviewing immediate postbiopsy mammograms for apparent hematoma, patients were then called 24-48 hours postprocedure and asked about palpable hematoma and breast bruise. Reichman et al. then reviewed medical records for clinically significant postbiopsy hematoma: hematoma requiring drainage, primary care or emergency department visit for persistent symptoms, or hospital admission. Finally, bleeding events were compared among groups.

Ultimately, imaging-apparent hematoma occurred in 3%, 6%, and 7%; palpable hematoma in 2%, 4%, and 4%; and breast bruise in 2%, 1%, and 6%, of patients without AT use, patients discontinuing AT, and patients maintaining AT, respectively, during breast CNB. The authors also reported that no patient developed clinically significant hematoma after biopsy.

Noting their findings “support the overall safety of maintaining AT during breast CNB,” Reichman and colleagues concluded that developing concomitant institutional policies and professional guidelines should be considered, too.

For more information: www.arrs.org


Related Content

Feature | Radiology Imaging | By Melinda Taschetta-Millane

It's been a fruitful month for itnonline.com! Here's a look at what ITN viewers found to be most interesting during the ...

Time June 01, 2023
arrow
News | Breast Density

May 25, 2023 — Researchers from the Mayo Clinic (Rochester, MN) and University of California, San Francisco confirmed ...

Time May 25, 2023
arrow
News | Breast Imaging

May 25, 2023 — GE HealthCare, a leader in breast cancer care technology and diagnostics, has today announced that NCCN ...

Time May 25, 2023
arrow
News | Ultrasound Women's Health

May 25, 2023 — According to an accepted manuscript published in ARRS’ own American Journal of Roentgenology (AJR), deep ...

Time May 25, 2023
arrow
News | Radiation Oncology

May 22, 2023 — Physicians and scientists from the UCLA Jonsson Comprehensive Cancer Center will discuss the latest ...

Time May 22, 2023
arrow
News | Mammography

May 22, 2023 — Incorrect advice by an AI-based decision support system could seriously impair the performance of ...

Time May 22, 2023
arrow
News | Computed Tomography (CT)

May 17, 2023 — According to an accepted manuscript published in ARRS’ own American Journal of Roentgenology (AJR), SARS ...

Time May 17, 2023
arrow
News | Breast Imaging

May 16, 2023 — DenseBreast-info.org has issued a statement which states that the USPSTF Guideline should not apply to ...

Time May 16, 2023
arrow
News | Breast Imaging

May 15, 2023 — RSNA updated its Statement on Screening for Breast Cancer, recognizing new recommendations from the ...

Time May 15, 2023
arrow
News | Breast Imaging

May 12, 2023 — The new United States Preventive Services Task Force (USPSTF) Breast Cancer Screening Recommendations are ...

Time May 12, 2023
arrow
Subscribe Now